354 related articles for article (PubMed ID: 21382127)
1. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model.
Ertilav M; Hur E; Bozkurt D; Sipahi S; Timur O; Sarsik B; Akcicek F; Duman S
Nephrology (Carlton); 2011 Aug; 16(6):552-7. PubMed ID: 21382127
[TBL] [Abstract][Full Text] [Related]
2. The effects of mycophenolate mofetil on encapsulated peritoneal sclerosis model in rats.
Hur E; Bozkurt D; Timur O; Bicak S; Sarsik B; Akcicek F; Duman S
Clin Nephrol; 2012 Jan; 77(1):1-7. PubMed ID: 22185962
[TBL] [Abstract][Full Text] [Related]
3. A novel angiogenesis inhibitor, sunitinib malate, in encapsulating peritoneal sclerosis.
Bozkurt D; Sarsik B; Hur E; Ertilav M; Karaca B; Timur O; Bicak S; Akcicek F; Duman S
J Nephrol; 2011; 24(3):359-65. PubMed ID: 21240876
[TBL] [Abstract][Full Text] [Related]
4. Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model.
Velioglu A; Tugtepe H; Asicioglu E; Yilmaz N; Filinte D; Arikan H; Koc M; Tuglular S; Kaya H; Ozener C
Ren Fail; 2013; 35(4):531-7. PubMed ID: 23473055
[TBL] [Abstract][Full Text] [Related]
5. TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.
Kariya T; Nishimura H; Mizuno M; Suzuki Y; Matsukawa Y; Sakata F; Maruyama S; Takei Y; Ito Y
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F167-F180. PubMed ID: 28978530
[TBL] [Abstract][Full Text] [Related]
6. Calcitriol decreases TGF-β1 and angiotensin II production and protects against chlorhexide digluconate-induced liver peritoneal fibrosis in rats.
Lee CJ; Subeq YM; Lee RP; Liou HH; Hsu BG
Cytokine; 2014 Jan; 65(1):105-18. PubMed ID: 24210651
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
8. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.
Duman S; Bozkurt D; Sipahi S; Sezak M; Ozkan S; Ertilav M; Sen S; Ok E
Adv Perit Dial; 2008; 24():104-10. PubMed ID: 18986012
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Rho-kinase alleviates peritoneal fibrosis and angiogenesis in a rat model of peritoneal dialysis.
Peng W; Zhou Q; Ao X; Tang R; Xiao Z
Ren Fail; 2013 Aug; 35(7):958-66. PubMed ID: 23859538
[TBL] [Abstract][Full Text] [Related]
10. The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis.
Bozkurt D; Bicak S; Sipahi S; Taskin H; Hur E; Ertilav M; Sen S; Duman S
Perit Dial Int; 2008 Nov; 28 Suppl 5():S53-7. PubMed ID: 19008543
[TBL] [Abstract][Full Text] [Related]
11. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models.
Io H; Hamada C; Ro Y; Ito Y; Hirahara I; Tomino Y
Kidney Int; 2004 May; 65(5):1927-36. PubMed ID: 15086936
[TBL] [Abstract][Full Text] [Related]
12. Effects of liposome-encapsulated clodronate on chlorhexidine gluconate-induced peritoneal fibrosis in rats.
Kushiyama T; Oda T; Yamada M; Higashi K; Yamamoto K; Oshima N; Sakurai Y; Miura S; Kumagai H
Nephrol Dial Transplant; 2011 Oct; 26(10):3143-54. PubMed ID: 21362737
[TBL] [Abstract][Full Text] [Related]
13. Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a rat model of peritoneal sclerosis.
Ada S; Ersan S; Sifil A; Unlu M; Kolatan E; Sert M; Sarioglu S; Yilmaz O; Camsari T
Int Urol Nephrol; 2015 Dec; 47(12):2047-51. PubMed ID: 26433885
[TBL] [Abstract][Full Text] [Related]
14. Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion.
Pletinck A; Van Landschoot M; Steppan S; Laukens D; Passlick-Deetjen J; Vanholder R; Van Biesen W
Nephrol Dial Transplant; 2012 Feb; 27(2):548-56. PubMed ID: 21750165
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats.
Ke CY; Lee CC; Lee CJ; Subeq YM; Lee RP; Hsu BG
Eur J Clin Invest; 2010 Apr; 40(4):301-9. PubMed ID: 20486991
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats.
Ro Y; Hamada C; Inaba M; Io H; Kaneko K; Tomino Y
Nephrol Dial Transplant; 2007 Oct; 22(10):2838-48. PubMed ID: 17545675
[TBL] [Abstract][Full Text] [Related]
17. Can N-acetylcysteine preserve peritoneal function and morphology in encapsulating peritoneal sclerosis?
Bozkurt D; Hur E; Ulkuden B; Sezak M; Nar H; Purclutepe O; Sen S; Duman S
Perit Dial Int; 2009 Feb; 29 Suppl 2():S202-5. PubMed ID: 19270218
[TBL] [Abstract][Full Text] [Related]
18. Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats.
Subeq YM; Ke CY; Lin NT; Lee CJ; Chiu YH; Hsu BG
Cytokine; 2011 Feb; 53(2):223-30. PubMed ID: 21129996
[TBL] [Abstract][Full Text] [Related]
19. By reducing TGF beta 1, octreotide lessens the peritoneal derangements induced by a high glucose solution.
Günal AI; Duman S; Sen S; Unsal A; Terzioğlu E; Akçiçek F; Basci A
J Nephrol; 2001; 14(3):184-9. PubMed ID: 11439742
[TBL] [Abstract][Full Text] [Related]
20. Impact of rapamycin on peritoneal fibrosis and transport function.
Xu T; Xie JY; Wang WM; Ren H; Chen N
Blood Purif; 2012; 34(1):48-57. PubMed ID: 22922738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
